Transgene Biotek

Transgene Biotek EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Transgene Biotek (526139.BO) as of Oct 30, 2026 is -7.43 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -11.23 M INR — a change of -33.89% (higher).

EBITDA

-7.43 MINR

YoY

-33.89%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Transgene Biotek is 2026 -7.43 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Transgene Biotek was 2025 -11.23 M INR. It decreases by -33.89% higher compared to the previous year.

The Transgene Biotek EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-6.73 M INR
Jan 1, 2020
-8.63 M INR
Jan 1, 2021
-2.56 M INR
Jan 1, 2022
-2.49 M INR
Jan 1, 2023
-4.33 M INR
Jan 1, 2024
-4.23 M INR
Jan 1, 2025
-11.23 M INR
Jan 1, 2026
-7.43 M INR
The Transgene Biotek EBITDA history
YEAREBITDAYoY
-7.43 MINR-33.89%
-11.23 MINR+165.30%
-4.23 MINR-2.22%
-4.33 MINR+74.22%
-2.49 MINR-2.73%
-2.56 MINR-70.40%
-8.63 MINR+28.27%
-6.73 MINR-40.50%
-11.31 MINR-29.09%
-15.95 MINR-9.87%
-17.70 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Transgene Biotek Stock analysis

What does Transgene Biotek do? Transgene Biotek Ltd. generates revenue through the sale of diagnostic kits and its portfolio of products, including oncology, auto-immunity, drug delivery, and biogenerics solutions. The company offers TrabiAAV, a platform for delivering miRNAs, ShRNAs, and immunogens in gene therapy, and TrabiORAL, which enables oral delivery of proteins and peptides for treating human diseases. Its TBL-1203 product strengthens cell-mediated immunity to eliminate HIV without retroviral therapy, while Tacrolimus suppresses the immune system to prevent organ transplant rejection. These products are targeted at healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The firm’s R&D focus on vaccines, oncology, and new drug delivery technologies supports its product development pipeline. TrabiAAV and TrabiORAL are positioned as innovative delivery platforms, while TBL-1203 and Tacrolimus address specific medical needs in HIV treatment and transplant medicine. The company’s diagnostic kits cater to clinical laboratories and hospitals requiring reliable testing solutions for oncology and autoimmune conditions. Transgene Biotek Ltd. serves healthcare professionals, pharmaceutical firms, and research organizations through its specialized products. Its oncology and auto-immunity kits are used in diagnostic settings, while its therapeutic platforms like TrabiAAV and TrabiORAL support drug development for complex diseases. The company’s focus on biogenerics and novel delivery systems aligns with market demands for cost-effective and targeted therapies. Transgene Biotek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene Biotek stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Transgene Biotek is -7.43 M INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Transgene Biotek changed from -11.23 M INR to -7.43 M INR, representing a -33.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Transgene Biotek since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Transgene Biotek historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Transgene Biotek

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Transgene Biotek